세계의 녹내장 시장 : 유형, 진단 방법, 치료법, 최종 사용자, 연령대별 예측(2025-2030년)

The Glaucoma Market was valued at USD 7.23 billion in 2023, expected to reach USD 7.60 billion in 2024, and is projected to grow at a CAGR of 5.56%, to USD 10.56 billion by 2030.

Glaucoma, a leading cause of irreversible blindness globally, demands extensive market research due to the growing aging population and increasing prevalence of the disease. The scope of this market includes a diverse array of diagnostic equipment, surgical devices, pharmaceuticals, and therapeutic solutions aimed at managing and treating glaucoma. The necessity for advanced glaucoma treatments is underscored by the need to prevent vision loss, thus ensuring a substantial quality of life for patients. Applications span clinical settings, research institutions, and healthcare facilities, utilizing surgical advancements, innovative drug delivery systems, and enhanced diagnostic tools to better manage intraocular pressure and retinal health. The end-use scope is broad, encompassing hospitals, specialized ophthalmology clinics, and home care settings, with an increasing trend toward personalized medicine. Market growth is significantly influenced by factors such as technological advancements in surgical and diagnostic devices, higher awareness among patients due to robust community outreach, and government initiatives to boost research and preventive measures. Emerging opportunities lie in developing minimally invasive surgical techniques, AI and IoT-based diagnostic tools, and personalized therapeutic approaches. However, market growth faces limitations such as high costs of treatment, lack of equitable access in low-income regions, and regulatory hurdles. Moreover, complex pathophysiology of glaucoma and its asymptomatic nature pose challenges in early diagnosis and treatment adherence. Innovating in areas like gene therapy, neuroprotection, sustained-release drug delivery systems, and telemedicine-based patient management could provide a competitive edge. The market's nature is dynamic, fostering collaboration between biotech firms, healthcare providers, and academic institutions. Businesses are recommended to focus on collaborative research, investing in emerging digital health solutions, and expanding into untapped markets to seize latent growth potential and improve glaucoma management on a global scale.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Market

The Glaucoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
  • Increasing utilization of combination therapies in glaucoma treatment fostering market development
  • Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
  • Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
• Market Restraints
  • Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
  • Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
• Market Opportunities
  • Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
  • Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
  • Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
• Market Challenges
  • Lack of awareness and education on early detection of glaucoma symptoms among the general population
  • Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Market

A detailed market share analysis in the Glaucoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Market

A strategic analysis of the Glaucoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Market, highlighting leading vendors and their innovative profiles. These include Aerie Pharmaceuticals, Alcon, Allergan, Allergan (acquired by Abbvie), Bausch Health, EyeGate Pharmaceuticals, Eyenovia, Glaukos Corporation, Inotek Pharmaceuticals, Johnson & Johnson, Merck, Nicox, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Santen Pharmaceutical, Teva Pharmaceutical, and Valeant Pharmaceuticals International.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Angle-Closure Glaucoma, Normal-Tension Glaucoma, and Primary Open-Angle Glaucoma.
• Based on Diagnosis Method, market is studied across Gonioscopy, Tonometry, and Visual Field Test.
• Based on Treatment, market is studied across Laser Treatment, Medication, and Surgery. The Laser Treatment is further studied across Argon Laser Trabeculoplasty and Selective Laser Trabeculoplasty. The Medication is further studied across Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, and Prostaglandin Analogs. The Surgery is further studied across Drainage Implants, Minimally Invasive Glaucoma Surgery, and Trabeculectomy.
• Based on End-User, market is studied across Ambulatory Surgery Centers, Hospitals, Ophthalmic Clinics, and Research Institutes.
• Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
    • 5.1.1.2. Increasing utilization of combination therapies in glaucoma treatment fostering market development
    • 5.1.1.3. Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
    • 5.1.1.4. Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
  • 5.1.2. Restraints
    • 5.1.2.1. Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
    • 5.1.2.2. Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
    • 5.1.3.2. Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
    • 5.1.3.3. Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness and education on early detection of glaucoma symptoms among the general population
    • 5.1.4.2. Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glaucoma Market, by Type

• 6.1. Introduction
• 6.2. Angle-Closure Glaucoma
• 6.3. Normal-Tension Glaucoma
• 6.4. Primary Open-Angle Glaucoma

7. Glaucoma Market, by Diagnosis Method

• 7.1. Introduction
• 7.2. Gonioscopy
• 7.3. Tonometry
• 7.4. Visual Field Test

8. Glaucoma Market, by Treatment

• 8.1. Introduction
• 8.2. Laser Treatment
  • 8.2.1. Argon Laser Trabeculoplasty
  • 8.2.2. Selective Laser Trabeculoplasty
• 8.3. Medication
  • 8.3.1. Alpha Agonists
  • 8.3.2. Beta Blockers
  • 8.3.3. Carbonic Anhydrase Inhibitors
  • 8.3.4. Prostaglandin Analogs
• 8.4. Surgery
  • 8.4.1. Drainage Implants
  • 8.4.2. Minimally Invasive Glaucoma Surgery
  • 8.4.3. Trabeculectomy

9. Glaucoma Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgery Centers
• 9.3. Hospitals
• 9.4. Ophthalmic Clinics
• 9.5. Research Institutes

10. Glaucoma Market, by Age Group

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Americas Glaucoma Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Glaucoma Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Glaucoma Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aerie Pharmaceuticals
• 2. Alcon
• 3. Allergan
• 4. Allergan (acquired by Abbvie)
• 5. Bausch Health
• 6. EyeGate Pharmaceuticals
• 7. Eyenovia
• 8. Glaukos Corporation
• 9. Inotek Pharmaceuticals
• 10. Johnson & Johnson
• 11. Merck
• 12. Nicox
• 13. Novartis
• 14. Pfizer
• 15. Regeneron Pharmaceuticals
• 16. Roche
• 17. Sanofi
• 18. Santen Pharmaceutical
• 19. Teva Pharmaceutical
• 20. Valeant Pharmaceuticals International